TD Waterhouse Canada Inc. Has $26.55 Million Stock Position in AbbVie Inc. $ABBV

TD Waterhouse Canada Inc. boosted its stake in AbbVie Inc. (NYSE:ABBV) by 98.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 108,725 shares of the company’s stock after purchasing an additional 53,885 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in AbbVie were worth $26,551,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. LexAurum Advisors LLC increased its holdings in AbbVie by 9.4% in the second quarter. LexAurum Advisors LLC now owns 1,790 shares of the company’s stock worth $332,000 after purchasing an additional 154 shares in the last quarter. Truist Financial Corp lifted its position in shares of AbbVie by 6.9% during the 2nd quarter. Truist Financial Corp now owns 2,181,263 shares of the company’s stock valued at $404,886,000 after acquiring an additional 140,414 shares during the period. Finally, Alley Investment Management Company LLC boosted its position in shares of AbbVie by 1.0% during the 2nd quarter. Alley Investment Management Company LLC now owns 117,719 shares of the company’s stock worth $21,851,000 after purchasing an additional 1,156 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the subject of several research reports. BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a research report on Thursday, January 15th. JPMorgan Chase & Co. lifted their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Morgan Stanley lifted their target price on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $249.37.

AbbVie Trading Down 2.2%

ABBV opened at $218.99 on Thursday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a market cap of $387.04 billion, a PE ratio of 165.90, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The company has a 50 day moving average of $224.85 and a 200 day moving average of $218.01.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the company earned $3.00 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Retrospective look: an analysis of why AbbVie outperformed in 2025 highlights management’s handling of blockbuster patent cliffs and portfolio transitions, supporting investor confidence in AbbVie’s strategy and cash returns. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Berenberg raised its price target to $275 (from $270) and kept a Buy rating, citing momentum for Skyrizi and Rinvoq — a bullish signal from an institutional analyst that can support upside. Berenberg Grows More Confident in AbbVie
• Positive Sentiment: AbbVie and Novartis announced multi‑billion dollar licensing arrangements for oncology and Alzheimer’s treatments — a pipeline/collaboration boost that could add long-term revenue optionality. AbbVie and Novartis Announce Billion Dollar Licensing Deals
• Positive Sentiment: Clinical/dev updates: coverage discusses a bispecific trial win and AbbVie’s R&D commitments that could strengthen the growth narrative if results translate to approvals. Does AbbVie’s Bispecific Trial Win…
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector to deliver risankizumab — operational progress that could improve dosing convenience and commercial uptake. AbbVie Advances Risankizumab Delivery
• Positive Sentiment: Allergan Aesthetics released pooled Phase 3 and Phase 4 data across injectables at IMCAS, underscoring strength in the aesthetics business line. Allergan Aesthetics Unveils New Data
• Positive Sentiment: On-air analyst support: a CNBC guest recommended staying long AbbVie, a short-term endorsement that can help sentiment. AbbVie on CNBC’s ‘Final Trades’
• Neutral Sentiment: Options activity: commentary notes unusual options movement, worth watching for short-term volatility but not definitive direction. Is the Options Market Predicting a Spike?
• Neutral Sentiment: Insider/holder note: a small asset manager disclosed a modest stake increase — a minor vote of confidence but immaterial to market cap. Belpointe Asset Management Increases Stake
• Neutral Sentiment: Corporate philanthropy: the AbbVie Foundation opened applications for a health equity accelerator — positive PR but unlikely to move the stock. AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: Policy risk: CMS named several AbbVie drugs for the third cycle of Medicare Drug Price Negotiations — a direct potential headwind to pricing and margins if negotiations lower reimbursement. US Medicare names Eli Lilly, Pfizer and AbbVie drugs
• Negative Sentiment: Earnings outlook: a Zacks preview said AbbVie lacks the setup for a clear earnings beat next week — a factor that can pressure near-term multiple and stock momentum. AbbVie Reports Next Week
• Negative Sentiment: Analyst change: Citigroup trimmed its price target to $230 and moved to Neutral, signaling less near-term upside from analyst coverage. Citigroup Lowers Price Target

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.